Canada: Applying The Rules

Last Updated: March 12 2014
Article by Susan Keri

Several notable developments in Canadian trademark law and practice during the past year are relevant to the pharmaceutical trademark field.

In Canada, the selection of a brand name for a prescription drug must be assessed bearing in mind both regulatory issues handled by Health Canada and trademark registration issues pursuant to the Trademarks Act. If a product name is approved by Health Canada, it does not necessarily follow that the name will be registrable as a trademark; and similarly, if a name is found to be registrable as a trademark, this does not mean that the name will be accepted by Health Canada. Health Canada considers the issue of drug name confusion from a health and safety perspective. By contrast, the selection of a trademark under the Trademarks Act focuses on the likelihood of confusion as to the source of manufacture of the products.

Drug names and Health Canada regulatory approval

The Food and Drug Regulations require a manufacturer to file a new drug submission containing sufficient information and material to enable Health Canada to assess the safety and effectiveness of the drug, including a statement of the brand name. If there are safety concerns, Health Canada may refuse to issue a notice of compliance for new drugs, or a drug identification number for new and existing drugs, both of which are necessary in order to market a pharmaceutical product in Canada.

In an effort to provide clarification regarding the brand-name submission process for proposed drug names, and to reduce the risk of medication errors related to similar drug names, Health Canada drafted a guidance for industry – Drug Name Review: Look-alike Sound-alike (LA/SA) Health Product Names – which came into force in 2006. Pursuant to this guidance, manufacturers are required to submit various materials, data and information to assist Health Canada in assessing the potential for confusion between a new drug name and that of an existing product. However, a review of new drug name submissions since the release of the 2006 guidance revealed significant variations in the amount, type and quality of evidence submitted by manufacturers, largely due to the absence of a clear direction on the process to be followed and the risk assessment methods to employ.

With a view to addressing some of the deficiencies in the 2006 guidance, Health Canada released a draft revised guidance document – Review of Drug Names for Look-alike Sound-alike (LA/SA) Attributes – on February 19 2013. The revised guidance is intended to provide more direction on the process to be followed and the information to be submitted to Health Canada regarding the issue of confusion between a proposed drug name and an existing product.

The revised guidance provides more specific procedures and risk assessment methods for manufacturers to follow when submitting a proposed drug name to Health Canada for approval, including use of a health product name search engine and two simulation tests: psycholinguistic testing and medication use testing.

Consultation on the revised guidance was open from February 19 2013 to April 19 2013. During this time, Health Canada met with individual stakeholders to hear their concerns. Most industry comments focused on the requirement for psycholinguistic testing, which was considered to be too stringent and exacting – particularly when compared to regulations of other countries – with no significant benefits.

In response to industry concerns, Health Canada stated that it would revise the guidance document. Regarding the issue of psycholinguistic testing, it indicated that it may be moved to an appendix to the guidance as an 'optional' test.

The final version of the guidance is expected to take effect in late 2013 or early 2014. Health Canada has proposed at least a one-year transition period during which it will not enforce the new guidance requirements.

Drug names and trademark registration

As noted above, the drug name approval process in Canada is separate and distinct from trademark registration.

In the case of trademark registration, the Trademarks Office must determine whether the co-existence of two similar drug names is likely to cause confusion in the marketplace as to the source of origin of the products. Public health concerns, such as medical risks associated with drug name mistakes, are not, strictly speaking, relevant to the issue of trademark registration.

However, recent Canadian jurisprudence suggests that health and safety concerns may become increasingly relevant when assessing the issue of confusion between drug names for trademark registration purposes. In Sanofi-Aventis v GlaxoSmithKline Biologicals SA ((2010), 89 CPR (4th) 378 (TMOB)), the Trademarks Opposition Board (TMOB) considered the issue of medication errors as a surrounding circumstance contributing to the likelihood of confusion between the trademarks PACIRIX and PLAVIX, and found the marks to be confusing, even though they were associated with different pharmaceutical preparations and end uses.

Non-traditional marks

Colour and shape

In Canada, a trademark consisting of colour applied to the shape of a product is inherently registrable. However, in the pharmaceutical field, there is a high evidential burden on the applicant to establish that the mark serves to distinguish the wares or services of the trademark owner from those of others. An applicant must establish that the colour mark is distinctive in the entire pharmaceutical field, and not only with respect to the specific preparation(s) with which it is associated. Moreover, the applicant must establish that the relevant market – namely, physicians, pharmacists and patients – relates the trademark to a single source of manufacture and uses it to make their prescribing, dispensing or purchasing choices. In the case of colour marks, this is an onerous burden of proof.

The recent TMOB decision in Canadian Generic Pharmaceutical Association v Pfizer Products Inc (2013 TMOB 27) reinforces the difficulty of securing registered trademark protection for marks consisting of colour applied to a pharmaceutical tablet or capsule in Canada. The case involved an opposition by the Canadian Generic Pharmaceutical Association to the registration by Pfizer Products Inc of its blue shaped tablet (VIAGRA).

In this case, the association was able to demonstrate that the colour and shape of the mark did not distinguish it from other pharmaceutical tablets and capsules, given the high number of blue pills that were actively marketed in Canada. Moreover, while the TMOB was prepared to accept that Pfizer's mark was distinctive among patients, it held that the evidence was insufficient to demonstrate that the mark was distinctive among pharmacists and physicians. Thus, the application was refused.

While the outcomes of applications to register colour tablet or capsule marks are highly dependent on the nature and extent of the evidence filed, the onus on the applicant is nevertheless significant, and invariably applications for registration of such marks are refused.


The Federal Court of Canada recently reversed the long-standing policy of the Canadian Intellectual Property Office (CIPO) regarding the registrability of sound marks in Canada. After a two-decade legal battle in which Metro-Goldwyn-Mayer (MGM) sought to register the sound of a roaring lion as a trademark, the Federal Court set aside CIPO's refusal and MGM's sound mark application issued to registration on July 31 2012. Prompted by the Federal Court decision, CIPO announced that it would accept applications to register sound marks.

The MGM decision and the resulting change in Canadian practice have brought Canada into line with many other countries that have long since recognised the registrability of sound marks. Pharmaceutical companies which use musical sounds and jingles in the branding of their products and services will no doubt welcome the shift in Canadian law and practice.

Anti-counterfeiting and enforcement

The magnitude of counterfeit pharmaceuticals in Canada remains relatively small in comparison to other industrialised countries, and there is no counterpart in Canada to the customs seizure regimes in the United States and many countries worldwide. Moreover, Canada does not have a trademark recordal regime or any other recordal regime for IP rights. Equally problematic is that customs officials in Canada will not act directly to search and seize goods independently that violate a trademark owner's rights.

The sale of counterfeit health products is governed primarily by the Customs Act, the Trademarks Act and the Copyright Act. In addition, selling counterfeit health products is a violation of the Criminal Code. However, the relevant legislation has proved difficult for rights holders to use effectively in the face of counterfeiting activities in Canada.

On October 16 2013 the Canadian government introduced Bill C-8, the Combating Counterfeit Products Act, to amend the Copyright Act and the Trademarks Act and make consequential amendments to other acts. It introduces amendments to the Copyright Act and Trademarks Act that will significantly improve border measures for counterfeit goods in Canada. (Bill C-8 was originally introduced as Bill C-56 earlier in 2013 and contains the same content).

Under Bill C-8, both the Trademarks Act and Copyright Act will be amended to include provisions that will grant the Canada Border Services Agency (CBSA) increased powers to prevent counterfeit goods from entering Canada. In addition, a copyright or registered trademark owner can file for a standing two-year request for assistance from the CBSA. During this period, the owner is provided with a sample of the goods and can request information to assist it in identifying the source of the counterfeit products. The proposed legislation also exposes offenders to fines of up to C$1 million and/or imprisonment.

The new assistance programme is available only with respect to registered trademarks and not common law trademark rights. Therefore, trademark owners would be well advised to register all marks that are potential counterfeiting targets in Canada.

This article first appeared in World Trademark Review magazine issue 47,published by The IP Media Group.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Susan Keri
In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.